You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
皓元醫藥(688131.SH):2024年度淨利潤2億元,同比增長60.83%
格隆匯 02-27 19:16

格隆匯2月27日丨皓元醫藥(688131.SH)公佈2024年度業績快報,報告期內,公司實現營業總收入225,773.20萬元,同比增長20.09%;實現歸屬於母公司所有者的淨利潤20,497.94萬元,同比增長60.83%;實現歸屬於母公司所有者的扣除非經常性損益的淨利潤17,261.03萬元,同比增長56.74%。

公司始終秉持長期主義理念,穩健推進“產業化、全球化、品牌化”發展戰略。2024年,持續聚焦主業,深化國內市場精細化佈局,聚焦客戶需求,全面升級服務品質;強化品牌及海外商務團隊建設,發展國際合作夥伴關係,深度拓展海外市場;堅持創新驅動及質量管理並重,提升技術能級建設;強化內控體系及合規管理,深入推進精益化運營;同時進一步優化人員結構,構建人才梯隊,提升研發效率和管理效率,以確保全球競爭力並實現持續穩健發展的態勢。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account